We are live on ! Find out more
DCM

DAFNA Capital Management Portfolio holdings

AUM $440M
1-Year Est. Return 109.12%
This Fund
S&P 500
This Quarter Est. Return
-12.43%
1 Year Est. Return
+109.12%
3 Year Est. Return
+239.59%
5 Year Est. Return
+227.89%
10 Year Est. Return
+3,611.91%
AUM
$367M
AUM Growth
-$16.9M
Cap. Flow
+$54.7M
Cap. Flow %
14.9%
Top 10 Hldgs %
47.4%
Holding
97
New
3
Increased
38
Reduced
15
Closed
7

Top Buys

Rank Stock Value
1
XBI icon
State Street SPDR S&P Biotech ETF
XBI
+$25.8M
2
ASND icon
Ascendis Pharma A/S
ASND
+$10.2M
3
BHVN
Biohaven Pharmaceutical Holding Company Ltd.
BHVN
+$4.15M
4
ACET icon
Adicet Bio
ACET
+$3.02M
5
ALEC icon
Alector
ALEC
+$2.59M

Top Sells

Rank Stock Value
1
KRTX
Karuna Therapeutics, Inc. Common Stock
KRTX
+$2.3M
2
LONA
LeonaBio Inc
LONA
+$2.17M
3
COGT icon
Cogent Biosciences
COGT
+$1.67M
4
IMCR icon
Immunocore
IMCR
+$1.61M
5
NTUS
Natus Medical Inc
NTUS
+$1.49M

Sector Composition

Rank Sector Weight
1 Healthcare 80.91%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
APLS
26
DELISTED
Apellis Pharmaceuticals
APLS
$4.38M 1.19%
96,935
+3,000
+3% +$137K
MORF
27
DELISTED
Morphic Holding, Inc. Common Stock
MORF
$4.24M 1.16%
195,467
+14,000
+8% +$391K
CSII
28
DELISTED
Cardiovascular Systems, Inc.
CSII
$4.12M 1.12%
286,988
– –
IPSC icon
29
Century Therapeutics
IPSC
$364M
$3.99M 1.09%
475,367
+218,475
+85% +$2.14M
ISEE
30
DELISTED
IVERIC bio, Inc. Common Stock
ISEE
$3.87M 1.06%
402,476
+104,000
+35% +$1.31M
TPTX
31
DELISTED
Turning Point Therapeutics, Inc. Common Stock
TPTX
$3.65M 0.99%
48,452
-11,000
-19% -$489K
FSTX
32
DELISTED
F-star Therapeutics, Inc. Common Stock
FSTX
$3.61M 0.98%
576,881
-116,904
-17% -$394K
OTIC
33
DELISTED
Otonomy, Inc.
OTIC
$3.06M 0.83%
1,470,199
-27,315
-2% -$56.9K
ATRC icon
34
AtriCure
ATRC
$1.92B
$2.94M 0.8%
72,029
– –
KNTE
35
DELISTED
Kinnate Biopharma Inc. Common Stock
KNTE
$2.83M 0.77%
224,451
+76,300
+52% +$710K
AXGN icon
36
Axogen
AXGN
$2.27B
$2.72M 0.74%
332,103
– –
KALV
37
DELISTED
KalVista Pharmaceuticals
KALV
$2.61M 0.71%
265,663
+75,000
+39% +$827K
ETNB
38
DELISTED
89bio
ETNB
$2.47M 0.67%
766,774
+442,721
+137% +$1.34M
DICE
39
DELISTED
DICE Therapeutics, Inc. Common Stock
DICE
$2.44M 0.66%
156,904
+62,904
+67% +$1.08M
LKFT
40
Lakefront Biotherapeutics American Depositary Shares
LKFT
$1.78B
$2.38M 0.65%
42,675
– –
BCYC
41
Bicycle Therapeutics
BCYC
$269M
$2.2M 0.6%
131,200
+78,000
+147% +$1.64M
ITOS
42
DELISTED
iTeos Therapeutics
ITOS
$2.17M 0.59%
105,298
+16,000
+18% +$380K
AERI
43
DELISTED
Aerie Pharmaceuticals
AERI
$2.17M 0.59%
289,040
– –
KURA icon
44
Kura Oncology
KURA
$800M
$2.16M 0.59%
117,829
+4,500
+4% +$64.7K
AFMD
45
DELISTED
Affimed
AFMD
$1.9M 0.52%
68,628
+11,500
+20% +$394K
MRSN
46
DELISTED
Mersana Therapeutics
MRSN
$1.88M 0.51%
16,271
+2,160
+15% +$203K
ORIC icon
47
Oric Pharmaceuticals
ORIC
$1.15B
$1.86M 0.51%
+415,926
New +$1.66M
ARAY icon
48
Accuray
ARAY
$32M
$1.85M 0.5%
941,800
– –
SURF
49
DELISTED
Surface Oncology, Inc. Common Stock
SURF
$1.8M 0.49%
1,100,000
+420,000
+62% +$872K
BMEA icon
50
Biomea Fusion
BMEA
$84.6M
$1.64M 0.45%
136,935
-246,988
-64% -$1.45M
1
2
3 4

Similar funds

CDMG
Creek Drive Management Group San Francisco, California $439M AUM
STCG
Speece Thorson Capital Group Minnetonka, Minnesota $439M AUM 10.15% 1-Year Est. Return
SCP
SailingStone Capital Partners Houston, Texas $440M AUM 127.21% 1-Year Est. Return
CAAM
Cape Ann Asset Management London, United Kingdom $440M AUM 96.23% 1-Year Est. Return
HCM
Harvey Capital Management Palm Beach, Florida $439M AUM 37.68% 1-Year Est. Return
BOA
Birnam Oak Advisors New York $441M AUM 37.12% 1-Year Est. Return
ECA
Endeavour Capital Advisors Greenwich, Connecticut $441M AUM 21.38% 1-Year Est. Return
WAS
Winch Advisory Services Appleton, Wisconsin $438M AUM 17.59% 1-Year Est. Return

DAFNA Capital Management's Q2 2022 Portfolio in Review

As of Q2 2022, DAFNA Capital Management held 97 positions worth $367M, down 4.4% from $384M the previous quarter. Its ten largest holdings account for 47% of the portfolio.

DAFNA Capital Management deployed $54.7M of net new capital in Q2 2022, opening 3 new positions and adding to 38 existing holdings. Its largest new stake was Keros Therapeutics: 39,000 shares worth $1.08M.

By sector, the portfolio is most concentrated in Healthcare at 81% of assets, down from 86% a quarter earlier.

On the sell side, the largest reduction was Karuna Therapeutics, Inc. Common Stock, an estimated $2.3M trimmed.

  • DAFNA Capital Management's largest Q2 2022 buy was Keros Therapeutics: 39,000 shares worth $1.08M.
  • DAFNA Capital Management added most to State Street SPDR S&P Biotech ETF in Q2 2022, an estimated $25.8M increase.
  • DAFNA Capital Management's biggest Q2 2022 reduction was Karuna Therapeutics, Inc. Common Stock, cutting an estimated $2.3M.
  • DAFNA Capital Management fully exited LeonaBio Inc in Q2 2022, selling an estimated $2.17M.
  • DAFNA Capital Management's ten largest holdings make up 47% of its $367M portfolio in Q2 2022.
  • DAFNA Capital Management opened 3 new positions and closed 7 in Q2 2022.
  • DAFNA Capital Management's portfolio value fell 4.4% quarter-over-quarter to $367M.

Based on DAFNA Capital Management's 13F filing for Q2 2022, filed 15 Aug 2022.